144 related articles for article (PubMed ID: 36843539)
21. Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma.
Murakami S; Uchida Y; Takeno S; Noguchi T; Matsumoto K; Shimoda H
Surg Today; 1997; 27(7):593-9. PubMed ID: 9306559
[TBL] [Abstract][Full Text] [Related]
22. Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways.
Kelley ST; Coppola D; Yeatman T; Marcet J
Clin Colorectal Cancer; 2005 Jul; 5(2):114-8. PubMed ID: 16098252
[TBL] [Abstract][Full Text] [Related]
23. [Expression of p53 in human esophageal carcinoma and pre-malignant lesions in the esophagus].
Dong Y; Liu S
Zhonghua Zhong Liu Za Zhi; 1996 Jan; 18(1):58-60. PubMed ID: 8732116
[TBL] [Abstract][Full Text] [Related]
24. The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma.
Palazzo JP; Kafka NJ; Grasso L; Chakrani F; Hanau C; Cuesta KH; Mercer WE
Hum Pathol; 1997 Oct; 28(10):1189-95. PubMed ID: 9343326
[TBL] [Abstract][Full Text] [Related]
25. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
[TBL] [Abstract][Full Text] [Related]
26. Expression and alteration of p53 and p21(waf1/cip1) influence the sensitivity of chemoradiation therapy for esophageal cancer.
Shimoyama S; Konishi T; Kawahara M; Aoki F; Harada N; Shimizu S; Murakami T; Kaminishi M
Hepatogastroenterology; 1998; 45(23):1497-504. PubMed ID: 9840093
[TBL] [Abstract][Full Text] [Related]
27. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.
Vallböhmer D; Kuhn E; Warnecke-Eberz U; Brabender J; Hoffmann AC; Metzger R; Baldus SE; Drebber U; Hoelscher AH; Schneider PM
Pharmacogenomics; 2008 Jun; 9(6):681-90. PubMed ID: 18518847
[TBL] [Abstract][Full Text] [Related]
28. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
Redston M; Noffsinger A; Kim A; Akarca FG; Rara M; Stapleton D; Nowden L; Lash R; Bass AJ; Stachler MD
Gastroenterology; 2022 Feb; 162(2):468-481. PubMed ID: 34757142
[TBL] [Abstract][Full Text] [Related]
29. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
Abraham SC; Wang H; Wang KK; Wu TT
Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
[TBL] [Abstract][Full Text] [Related]
30. p53 and Ki-67 in Barrett's carcinoma: is there any value to predict recurrence after circumferential endoscopic mucosal resection?
Lopes CV; Mnif H; Pesenti C; Bories E; Monges G; Giovannini M
Arq Gastroenterol; 2007; 44(4):304-8. PubMed ID: 18317648
[TBL] [Abstract][Full Text] [Related]
31. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases.
Thurberg BL; Duray PH; Odze RD
Hum Pathol; 1999 Jul; 30(7):745-52. PubMed ID: 10414492
[TBL] [Abstract][Full Text] [Related]
32. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
33. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
34. Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss.
Singh N; Leen SL; Han G; Faruqi A; Kokka F; Rosenthal A; Jiang XR; Kim R; McAlpine JN; Gilks CB
Am J Surg Pathol; 2015 Jan; 39(1):52-60. PubMed ID: 25025443
[TBL] [Abstract][Full Text] [Related]
35. Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA.
Wang YZ; Cao YQ; Wu JN; Chen M; Cha XY
World J Gastroenterol; 2005 Jan; 11(1):46-50. PubMed ID: 15609395
[TBL] [Abstract][Full Text] [Related]
36. [Clinicopathological features of basal cell type dysplasia of esophagus].
Hou WH; Duan XK; Hou WD; Ma LJ; Niu JW; Zhou SL; Jin ML
Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):638-644. PubMed ID: 34078053
[No Abstract] [Full Text] [Related]
37. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene.
Seta T; Imazeki F; Yokosuka O; Saisho H; Suzuki T; Koide Y; Isono K
Dig Dis Sci; 1998 Feb; 43(2):279-89. PubMed ID: 9512119
[TBL] [Abstract][Full Text] [Related]
38. Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy.
Shia J; Tickoo SK; Guillem JG; Qin J; Nissan A; Hoos A; Stojadinovic A; Ruo L; Wong WD; Paty PB; Weiser MR; Minsky BD; Klimstra DS
Am J Surg Pathol; 2002 Jul; 26(7):863-72. PubMed ID: 12131153
[TBL] [Abstract][Full Text] [Related]
39. Polyoma virus-associated cellular changes in the urine and bladder biopsy samples: a cytohistologic correlation.
Herawi M; Parwani AV; Chan T; Ali SZ; Epstein JI
Am J Surg Pathol; 2006 Mar; 30(3):345-50. PubMed ID: 16538054
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study.
Klump B; Hsieh CJ; Holzmann K; Borchard F; Gaco V; Greschniok A; Eckardt VF; Bettendorf U; Gregor M; Porschen R
Z Gastroenterol; 1999 Oct; 37(10):1005-11. PubMed ID: 10549095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
